Activation of JNK pathway in spinal astrocytes contributes to acute ultra-low-dose morphine thermal hyperalgesia

Pain

Volumn 156, Issue 7, 2015, Pages 1265-1275

  Sanna, Maria Domenica ^a   Ghelardini, Carla ^a   Galeotti, Nicoletta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Astrocyte; Hyperalgesia; JNK; Morphine; Protein kinase C

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; PROTEIN C JUN; PROTEIN KINASE C GAMMA; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; HYPERALGESIA; IMMUNOFLUORESCENCE; LOW DRUG DOSE; MALE; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPINAL ASTROCYTE; SPINAL CORD; THERMAL HYPERALGESIA; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HEAT; METABOLISM; PHYSIOLOGY;

ANIMALS; ASTROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HOT TEMPERATURE; HYPERALGESIA; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MORPHINE; SPINAL CORD;

EID: 84936109838     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000164     Document Type: Article

References (56)

1. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systemic review. Anesthesiology 2006;104:570-87.
2. Angst MS, KoppertW, Pahl I, Clark DJ, SchmelzM. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. PAIN 2003;10:49-57.
3. Celè rier E, Laulin JP, Corcuff J-B, Le Moal L, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001;21:4074-80.
4. Celè rier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000;92:465-72.
5. Chen ML, Cao H, Chu YX, Cheng LZ, Liang LL, Zhang YQ, Zhao ZQ. Role of P2X7 receptor-mediated IL-18/IL-18R signaling in morphine tolerance: multiple glial-neuronal dialogues in the rat spinal cord. J Pain 2012;13: 945-58.
6. Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, Chuang DM. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem 2003;84:566-75.
7. Chen YL, Law PY, Loh HH. Nuclear factor kappaB signaling in opioid functions and receptor gene expression. J Neuroimmune Pharmacol 2006;1:270-9.
8. Chu L, Angst M, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24: 479-96.
9. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 2003;4:511-9.
10. Crain SM, Shen KF. Acute thermal hyperalgesia elicited by low dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 2001;888:75-82.
11. Cui J, Zhang M, Zhang Y-Q, Xu Z-H. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin 2007;28:601-8.
12. De la Calle JL, Paino CL. A procedure for direct lumbar puncture in rats. Brain Res Bull 2002;59:245-50.
13. DeLeo JA, Tanga FY, Tawfik VL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 2004;10:40-52.
14. Esmaeili-Mahani S, Shimokawa N, Javan M, Maghsoudi N, Motamedi F, Koibuchi N, Ahmadiani A. Low-dose morphine induces hyperalgesia through activation of G alphas, protein kinase C, and L-type Ca 21 channels in rats. J Neurosci Res 2008;86:471-9.
15. Galeotti N, Bartolini A, Ghelardini C. The phospholipase C-IP3 pathway is involved in muscarinic antinociception. Neuropsychopharmacology 2003;28:888-97.
16. Galeotti N, Farzad M, Bianchi E, Ghelardini C. Potentiation of morphine analgesia by low dose of St. John's Wort in rodents and humans. J Pharmacol Sci 2014;124:409-17.
17. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C. Signaling pathway of morphine induced acute thermal hyperalgesia in mice. PAIN 2006;123:294-305.
18. Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000;93:409-17.
19. Guo R-X, Zhanga M, Liua W, Zhao C-M, Cui Y, Wang C-H, Fenga JQ, Chena PX. NMDA receptors are involved in upstream of the spinal JNK activation inmorphine antinociceptive tolerance. Neurosci Lett 2009;567:95-9.
20. Horvath RJ, Landry RP, Romero-Sandoval EA, DeLeo JA. Morphine tolerance attenuates the resolution of postoperative pain and enhances spinal microglial p38 and extracellular receptor kinase phosphorylation. Neuroscience 2010;169:843-54.
21. Ji RR. Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs 2004;5:71-5.
22. Ji R-R, Gereau RWIV,Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009;60:135-48.
23. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Zhang YQ. Protein kinases as potential targets for the treatment of pathological pain. Handb Exp Pharmacol 2007;177:359-89.
24. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
25. Kayser V, Besson JM, Guilbaud G. Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res 1987; 414:155-7.
26. Laulin JP, Larcher A, Celerier E, Le Moal M, Simonnet G. Long lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci 1998;10:782-5.
27. Lee M, Silverman S, Hansen H, Patel V, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Phys 2011;14:145-61.
28. Lim G, Wang S, Zeng Q, Sung B, Yang L, Mao J. Expression of spinal NMDA receptor and PKCgamma after chronic morphine is regulated by spinal glucocorticoid receptor. J Neurosci 2005;25:11145-54.
29. Liu CH, Chen-Hwen Cherng CH, Lin SL, Yeh CC,WuCT, Tai YH,WongCS. N-Methyl-d-aspartate receptor antagonist MK-801 suppresses glial proinflammatory cytokine expression in morphine-tolerant rats. Pharmacol Biochem Behav 2011;99:371-80.
30. Lohmann AB, Welch SP. Antisense to opioid receptors attenuate ATPgated K(1) channel opener-induced antinociception. Eur J Pharmacol 1999;384:147-52.
31. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. Re-wired ERKJNK signaling pathways in melanoma. Cancer Cell 2007;11;447-60.
32. Ma W, Quirion R. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin Ther Targets 2005;9:699-713.
33. Mao J. Opioid-induced abnormal pain sensitivity: implication in clinical therapy. PAIN 2002;100:213-7.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 2010;160:1573-6.
35. McMahon S, Malcangio M. Current challenges in glia-pain biology. Neuron 2009;64:46-54.
36. Melief EJ, Miyatake M, Bruchas MR, Chavkin C. Ligand-direct c-Jun N-terminal kinase activation disrupts opioid receptor signalling. Proc Natl Acad Sci U S A 2010;107:11608-13.
37. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23-36.
38. Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin induced neuropathy in rat. PAIN 2009;146:141-7.
39. Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, Fukuoka T, Tokunaga A, Noguchi K. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci 2004;24:10211-22.
40. Ozdemir E, Bagcivan I, Durmus N, Altun A, Gursoy S. The nitric oxide-cGMP signaling pathway plays a significant role in tolerance to the analgesic effect of morphine. Can J Physiol Pharmacol 2011;89: 89-95.
41. Pocock JM, Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci 2007;30:527-35.
42. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham operated rats. J Neurosci 2002;22:9980-9.
43. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6.
44. Sanchez-Blazquez P, Garcia-Espana A, Garzon J. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther 1997;280:1423-31.
45. Sanna MD, Ghelardini C, Galeotti N. Regionally selective activation of ERK and JNK in morphine paradoxical hyperalgesia: a step toward improving opioid pain therapy. Neuropharmacology 2014; 86:67-77.
46. Santamarta MT, Ulibarri I, Pineda J. Inhibition of neuronal nitric oxide synthase attenuates the development of morphine tolerance in rats. Synapse 2005;57:38-46.
47. Schwarzschild MA, Cole RL, Hyman SE. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. J Neurosci 1997;17:3455-66.
48. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001;39:281-6.
49. Van Elstraete AC, Sitbon P, Trabold F, Mazoit JX, Benhamou D. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine. Anesth Analg 2005; 101:1750-6.
50. Wan Q, Wang X, Wang YJ, Song L, Wang SH, Ho WZ. Morphine suppresses intracellular interferon-alpha expression in neuronal cells. J Neuroimmunol 2008;199:1-9.
51. WangW,MeiX-P,Wei Y-Y, ZhangM-M,ZhangT,WangW, XuL-X,WuS-X, Li Y-Q. Neuronal NR2B-containing NMDA receptor mediates spinal astrocytic c-Jun N-terminal kinase activation in a rat model of neuropathic pain. Brain Behav Immun 2011;25:1355-66.
52. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counterregulators of opioid analgesia. Trends Neurosci 2005;28:661-9.
53. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The toll of opioidinduced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009;30:581-91.
54. Wen Y-R, Tan P-H, Cheng J-K, Liu Y-C, Ji R-R. Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc 2011;110:487-94.
55. Zhou D, Chen ML, Zhang YQ, Zhao ZQ. Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J Neurosci 2010;30:8042-7.
56. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006;26: 3551-60.